Grégoire Y, Germain M, Delage G
Héma-Québec, Quebec City, QC, Canada.
Héma-Québec, Montréal, QC, Canada.
Vox Sang. 2018 May;113(4):339-344. doi: 10.1111/vox.12644. Epub 2018 Mar 6.
Since 25 May 2010, all donors at our blood centre who tested false-positive for HIV, HBV, HCV or syphilis are eligible for re-entry after further testing. Donors who have a second false-positive screening test, either during qualification for or after re-entry, are deferred for life. This study reports on factors associated with the occurrence of such deferrals.
Rates of second false-positive results were compared by year of deferral, transmissible disease marker, gender, age, donor status (new or repeat) and testing platform (same or different) both at qualification for re-entry and afterwards. Chi-square tests were used to compare proportions. Cox regression was used for multivariate analyses.
Participation rates in the re-entry programme were 42·1%: 25·6% failed to qualify for re-entry [different platform: 2·7%; same platform: 42·9% (P < 0·0001)]. After re-entry, rates of deferral for second false-positive results were 8·4% after 3 years [different platform: 1·8%; same platform: 21·4% (P < 0·0001)]. Deferral rates were higher for HIV and HCV than for HBV at qualification when tested on the same platform. The risk, when analysed by multivariate analyses, of a second deferral for a false-positive result, both at qualification and 3 years after re-entry, was lower for donors deferred on a different platform; this risk was higher for HIV, HCV and syphilis than for HBV and for new donors if tested on the same platform.
Re-entry is more often successful when donors are tested on a testing platform different from the one on which they obtained their first false-positive result.
自2010年5月25日起,我们血液中心所有HIV、HBV、HCV或梅毒检测呈假阳性的献血者在进一步检测后有资格重新献血。在重新献血资格审核期间或重新献血后进行第二次筛查呈假阳性的献血者将被终身延期献血。本研究报告了与此类延期献血发生相关的因素。
比较重新献血资格审核时及之后不同延期年份、传染病标志物、性别、年龄、献血者状态(新献血者或重复献血者)和检测平台(相同或不同)的第二次假阳性结果发生率。采用卡方检验比较比例。采用Cox回归进行多变量分析。
重新献血计划的参与率为42.1%:25.6%的人未获得重新献血资格[不同平台:2.7%;相同平台:42.9%(P<0.0001)]。重新献血后,3年后第二次假阳性结果的延期献血率为8.4%[不同平台:1.8%;相同平台:21.4%(P<0.0001)]。在相同平台上检测时,HIV和HCV在资格审核时的延期献血率高于HBV。通过多变量分析,在资格审核时和重新献血3年后,因假阳性结果导致第二次延期献血的风险,在不同平台上延期的献血者较低;如果在相同平台上检测,HIV、HCV和梅毒的这种风险高于HBV,且新献血者的风险更高。
当献血者在与首次获得假阳性结果不同的检测平台上进行检测时,重新献血更常成功。